ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cerecor, a two-year-old biotech firm based in Baltimore, has acquired worldwide rights from Merck & Co. to develop agents that inhibit catechol-O-methyltransferase. COMT is an enzyme that breaks down dopamine. COMT inhibitors, Cerecor says, could treat central nervous system diseases such as addictive behaviors and schizophrenia by increasing dopamine levels in affected areas of the brain. Under the agreement, Cerecor will evaluate more than 2,000 molecules and select candidates for clinical development.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter